Global Lymphatic Filariasis Market, By Diagnosis (Microscopic Examination, Serologic Techniques, Others), Treatment (Surgery, Medication, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029
Lymphatic Filariasis Market Analysis and Size
The global lymphatic filariasis market is expected to witness significant growth during the forecast period. Growing cases of elephantiasis drives the lymphatic filariasis market. However, increased incidences of elephantiasis and increased awareness programme by WHO for the treatment of Lymphatic filariasis will boost up the lymphatic filariasis market. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global lymphatic filariasis market in the forecast period 2022-2029. The expected CAGR of global lymphatic filariasis market is tend to be have a healthy CAGR in the mentioned forecast period. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Lymphatic filariasis commonly known as elephantiasis and it’s a neglected tropical disease. It is a parasitic disease caused by microscopic, thread-like worms that is only lives in human lymph system. It spreads from person to person through the mosquitoes bite causing pain, abnormal enlargement of body part and social stigma. Infection generally occurs in childhood stage and causing hidden damage to the lymphatic system. Most peoples affected by the parasite are asymptomatic and never show any clinical symptoms. Only small percentage of infected people may show the symptoms of “lymphedema”, which affects the arms, legs, breast and genitalia. It is of great importance to the healthcare sector and thus is expected to rise high in the forecast period
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Diagnosis (Microscopic Examination, Serologic Techniques, Others), Treatment (Surgery, Medication, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Cipla Inc (India), Amneal Pharmaceutical Inc (U.K.), Bausch Health (Canada), Pfizer Inc (U.S.), Hikma Pharmaceuticals Inc (U.S.), Norvartis AG (Switzerland), Teva Pharmaceutical Industries Ltd (Israel), Mylan N.V (U.S.), Johnsons & Johnsons Services Inc (U.S.), Boehringer Ingelheim International GmbH (U.S.), Strides Pharma Science Limited (India), GALDERMA LABORATORIES, L.P (U.S.), Pearl River Laboratories (U.S.)
|
|
Market Opportunities
|
|
Global Lymphatic Filariasis Market Dynamics
Drivers
- Increased Incidence of Lymphatic Filariasis
As per the reports of WHO in 2018, around 893 million people in 49 countries require preventive chemotherapy to stop the spread of lymphatic filariasis infection. It is estimated that around 25 million men are suffering with hydrocele and over 15 million people living with lymphoedema worldwide. Its prevalence is increasing and its treatment is of great importance to the healthcare sector.
- Rising Demand for Oral Drugs
Oral drugs is expected to boost the market growth. The segment is expected to accelerate the global market as most products are available in capsule and tablet form and it is a very feasible route of administration.
Opportunities
- Increased Drug Launches and Research Development
Several pharmaceutical companies focus on designing and developing new treatment options for this disease. For instance, AbbVie, Inc. is continuing its research on one innovative product called as ABBV-4083, in pipeline (phase I) for treatment of lymphatic filariasis. In addition to this, rise in government initiatives and increase in awareness about the disease among the general population boost the market growth. Furthermore, increase in health care funding and the growth in improvement in health care facilities lead to the growth of the global lymphatic filariasis market. This creates more opportunity in the market.
Restraints/Challenges
- Lack of Skilled Professionals
Lack of trained professionals who are unaware of the knowledge of the treatment methods for this disease could curb the growth of the global lymphatic filariasis market over a forecast period.
- High Cost
The huge expenditure of the treatment methods surely hamper the market growth.
This global lymphatic filariasis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global lymphatic filariasis market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Lymphatic Filariasis Market
Considering the present scenario, COVID-19 has left an unprecedented global public health crisis that has impacted practically every business. Transition of healthcare infrastructure toward managing COVID-19 has led to drug launch cancellations and delays in clinical trials.
The global cyanotic heart disease market witnessed a huge negative transition during the COVID-19 pandemic as there was a decline in patient hospitalizations, and only emergency and primary care services are available during COVID-19. Therefore, this has decrease the availability of diagnostic tests and impacted the sales of devices for congenital heart disease.
Global Lymphatic Filariasis Market Scope
The global lymphatic filariasis market is segmented on the basis of diagnosis, treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Diagnosis
- Microscopic Examination
- Serologic Techniques
- Others
Treatment
- Surgery
- Medication
- Others
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Lymphatic Filariasis Market Regional Analysis/Insights
The global lymphatic filariasis market is analysed and market size insights and trends are provided by diagnosis, treatment, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global lymphatic filariasis market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Middle-east and Africa is expected to have the highest market growth due to an increase in new product launch and demand for lymphatic filariasis treatment in emerging countries such as South Africa and others.
Asia-Pacific dominates the market due to large number of patients with lymphatic filariasis, early adoption of new products, and presence of major manufacturers.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Lymphatic Filariasis Market Share Analysis
The global lymphatic filariasis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global lymphatic filariasis market.
Key players operating in the global lymphatic filariasis market include:
- Cipla Inc (India)
- Amneal Pharmaceutical Inc (U.K.)
- Bausch Health (Canada)
- Pfizer Inc (U.S.)
- Hikma Pharmaceuticals Inc (U.S.)
- Norvartis AG (Switzerland)
- Teva Pharmaceutical Industries Ltd (Israel)
- Mylan N.V (U.S.)
- Johnsons & Johnsons Services Inc (U.S.)
- Boehringer Ingelheim International GmbH (U.S.)
- Strides Pharma Science Limited (India)
- GALDERMA LABORATORIES, L.P (U.S.)
- Pearl River Laboratories (U.S.)
SKU-